How Innoviva, Inc. stacks up

INVA · against 552 other Healthcare companies listed in US-listed

Overall

93/ 100

Near the top of its peers.

Ranked #4 of 553 · scores higher than 99% of peers

Bars: peers in each 10-point band of the overall score

5 peers with an overall score of 90–100, including INVA · Click a bar to see the companies

The four scores behind it

Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)

Valuation#14 of 589Score 94 / 100 · beats 97%Growth#70 of 455Score 91 / 100 · beats 83%Profitability#40 of 558Score 93 / 100 · beats 92%Risk#59 of 597Lower relative risk · safety 94 · beats 90%

Ranking by overall score

Top 5 and the companies ranked around INVA

Rank	Company	Market cap	Overall	Valuation	Growth	Profitability	Risk
1	Arbutus Biopharma CorporationABUS · US-listed	595M USD	97	96	98	99	0 / 2
1	Q32 Bio Inc.QTTB · US-listed	261M USD	97	93	—	98	0 / 2
3	Lakefront Biotherapeutics NVLKFT · US-listed	2.1B USD	96	96	99	93	0 / 2
4	Innoviva, Inc.INVA · US-listed	1.5B USD	93	94	91	93	0 / 2
5	Zevra Therapeutics, Inc.ZVRA · US-listed	609M USD	91	95	99	99	0 / 2
6	Incyte CorporationINCY · US-listed	23.8B USD	84	82	82	98	0 / 2
6	Nurix Therapeutics, Inc.NRIX · US-listed	2.7B USD	84	75	98	99	1 / 2
8	Aurinia Pharmaceuticals Inc.AUPH · US-listed	2.2B USD	82	90	92	96	1 / 2

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score

Bringing the fundamentals into focus…